AR (Ab-363) Antibody

What is the AR (Ab-363) Antibody and what epitope does it recognize?

The AR (Ab-363) Antibody is a rabbit polyclonal antibody designed to detect endogenous levels of total Androgen Receptor protein in human samples. It specifically recognizes an epitope around the phosphorylation site of tyrosine 363 (D-Y-Y(p)-N-F) in the human Androgen Receptor. This antibody was generated using a synthesized non-phosphopeptide derived from this region . Understanding the specific epitope recognition is crucial for interpreting experimental results and potential cross-reactivity patterns.

How does AR (Ab-363) antibody compare to other androgen receptor antibodies in terms of specificity?

The AR (Ab-363) antibody offers specificity for the androgen receptor by targeting a distinct epitope around the tyrosine 363 phosphorylation site. While other available AR antibodies may target different epitopes (such as phospho-specific antibodies targeting Ser94, Ser650, or antibodies recognizing AR-V7 splice variants), the Ab-363 antibody is designed to detect total AR protein regardless of phosphorylation status at other sites . When selecting between available options, researchers should consider which form of the receptor is relevant to their research question - whether total AR protein detection or specific post-translational modifications are of interest.

What principles should guide antibody selection for androgen receptor research?

When selecting antibodies for androgen receptor research, researchers should follow established antibody characterization principles that include:

• Genetic validation - Testing the antibody in AR knockout or knockdown models

• Orthogonal validation - Comparing antibody results with alternative detection methods

• Multiple antibody validation - Using different antibodies targeting the same protein to confirm specificity

• Recombinant expression validation - Testing the antibody against overexpressed AR

• Immunocapture MS validation - Using mass spectrometry to identify captured proteins

These approaches help ensure that the antibody truly detects the intended target and performs consistently in the experimental context being used.

What are the validated applications for AR (Ab-363) Antibody?

The AR (Ab-363) Antibody has been validated primarily for Western blot (WB) applications . While the manufacturer specifies WB as the validated application, researchers seeking to use this antibody for other techniques such as immunohistochemistry (IHC), immunofluorescence (IF), or immunoprecipitation (IP) should conduct additional validation experiments before proceeding with those applications. The antibody's performance in these additional applications would depend on its ability to recognize the epitope under different experimental conditions and fixation methods.

What is the recommended protocol for Western blot using AR (Ab-363) Antibody?

While specific optimization may be required for individual experimental systems, a general protocol for Western blot using AR (Ab-363) Antibody includes:

• Sample preparation: Extract proteins from cells/tissues using appropriate lysis buffer

• Protein quantification and normalization

• SDS-PAGE separation (typically 7-10% gels for AR detection)

• Transfer to membrane (PVDF or nitrocellulose)

• Blocking (typically 5% BSA or non-fat milk in TBST)

• Primary antibody incubation: AR (Ab-363) at optimized dilution (typically 1:500-1:2000), overnight at 4°C

• Washing with TBST (3-5 times, 5-10 minutes each)

• Secondary antibody incubation (anti-rabbit HRP or fluorescent conjugate)

• Washing with TBST (3-5 times, 5-10 minutes each)

• Detection using chemiluminescence or fluorescence imaging

Validation data from K562 cells treated with EGF (200ng/ml, 5mins) has been demonstrated for this antibody .

How should samples be prepared to optimize detection of androgen receptor using AR (Ab-363) Antibody?

For optimal detection of androgen receptor using AR (Ab-363) Antibody, consider these methodological approaches:

• Cell lysis optimization: Use buffers containing phosphatase inhibitors to preserve phosphorylation states (crucial since the epitope is near a phosphorylation site)

• Protein denaturation conditions: Mild to moderate denaturation conditions are typically optimal for detecting proteins with post-translational modifications

• Loading controls: Include appropriate loading controls and potentially positive controls (such as cell lines known to express AR)

• Sample handling: Minimize freeze-thaw cycles of protein samples as this can affect epitope recognition

• Signal enhancement: Consider using signal enhancement systems for low abundance targets

Remember that detection of endogenous AR may require optimization depending on expression levels in your experimental system.

What validation methods should be used to confirm specificity of AR (Ab-363) Antibody in new experimental systems?

When validating AR (Ab-363) Antibody in a new experimental system, researchers should employ multiple complementary approaches:

• Genetic approaches: Test the antibody in samples with genetic knockdown/knockout of AR to confirm absence of signal

• Peptide competition: Pre-incubate the antibody with the immunizing peptide to block specific binding

• Size verification: Confirm the detected protein is of the expected molecular weight for AR (~110 kDa)

• Positive controls: Include cell lines known to express AR (such as LNCaP or K562 cells)

• Negative controls: Include cell lines with minimal AR expression

• Treatment responsiveness: Verify that signal changes as expected with treatments known to affect AR (such as androgen stimulation or EGF treatment)

These validation steps are critical given that antibody performance can be context-dependent and should be performed by end users for each specific experimental application .

How can researchers distinguish between AR (Ab-363) Antibody binding to AR versus off-target proteins?

To distinguish specific AR binding from off-target interactions, researchers should:

• Utilize structural bioinformatics: Analyze potential cross-reactivity by sequence similarity searches of the epitope region (D-Y-Y(p)-N-F)

• Perform blocking experiments: Compare signals with and without competing peptide

• Employ orthogonal methods: Confirm AR detection using alternative antibodies targeting different AR epitopes

• Conduct immunoprecipitation followed by mass spectrometry: Identify all proteins captured by the antibody

• Use multiple antibody strategies: Compare results with independent antibodies against the same protein

Structure-guided antibody design and evaluation principles indicate that antibodies with improved complementarity to their target epitopes show enhanced specificity, which reduces off-target binding .

How should researchers document AR (Ab-363) Antibody validation for publication?

For publication, thorough documentation of AR (Ab-363) Antibody validation should include:

• Complete antibody identification: Catalog number, lot number, manufacturer, and RRID (Research Resource Identifier)

• Validation experiments: Detailed methods and results demonstrating specificity

• Positive and negative controls: Clear demonstration of controls used

• Optimization details: Dilution factors, incubation conditions, and detection methods

• Representative images: Full blots showing molecular weight markers and all visible bands

• Reproducibility evidence: Data from replicate experiments

This comprehensive documentation aligns with international efforts to improve antibody reporting standards and enhances experimental reproducibility .

What are common causes of inconsistent results with AR (Ab-363) Antibody and how can they be addressed?

Inconsistent results with AR (Ab-363) Antibody may stem from several factors:

• Epitope masking: The tyrosine 363 region may be masked by protein-protein interactions or post-translational modifications

  • Solution: Optimize sample preparation to ensure epitope accessibility

• Variable phosphorylation: The antibody recognizes an area near a phosphorylation site

  • Solution: Standardize cell stimulation conditions and include phosphatase inhibitors

• Protein degradation: AR can undergo proteolytic degradation

  • Solution: Use fresh samples and appropriate protease inhibitors

• Lot-to-lot variability: Polyclonal antibody preparations may show variation

  • Solution: Validate each new lot before use in critical experiments

• Cross-reactivity: Potential binding to proteins with similar epitopes

  • Solution: Include appropriate blocking controls and validate specificity

How can signal-to-noise ratio be improved when using AR (Ab-363) Antibody for Western blot?

To improve signal-to-noise ratio with AR (Ab-363) Antibody:

• Optimize blocking conditions: Test different blocking agents (BSA, milk, commercial blockers) to reduce background

• Titrate antibody concentration: Perform a dilution series to find optimal primary antibody concentration

• Extend washing steps: Increase number and duration of washes

• Adjust incubation parameters: Optimize temperature and duration of primary antibody incubation

• Use high-quality secondary antibodies: Select secondary antibodies with minimal cross-reactivity

• Employ signal enhancement systems: Consider using amplification systems for weak signals

• Optimize exposure times: For chemiluminescence detection, test multiple exposure times

What approaches should be taken if AR (Ab-363) Antibody shows unexpected bands or patterns?

When unexpected bands or patterns appear with AR (Ab-363) Antibody:

• Verify AR isoforms: Compare band patterns with known AR isoforms and splice variants

• Check for degradation products: Run time-course experiments with protease inhibitors

• Evaluate post-translational modifications: Consider whether modifications alter electrophoretic mobility

• Test different lysis conditions: Compare various cell lysis methods to determine if extraction conditions affect results

• Perform peptide competition: Confirm which bands are competed away by the immunizing peptide

• Conduct immunoprecipitation followed by mass spectrometry: Identify unexpected proteins detected by the antibody

• Compare with other AR antibodies: Use antibodies targeting different AR epitopes to confirm band identity

How can AR (Ab-363) Antibody be utilized to study phosphorylation-dependent signaling of androgen receptor?

The AR (Ab-363) Antibody recognizes an epitope near the tyrosine 363 phosphorylation site, making it potentially valuable for studying phosphorylation-dependent signaling:

• Comparative analysis: Use in conjunction with phospho-specific AR antibodies (such as those targeting phospho-Ser94 or phospho-Ser650) to examine relationships between different phosphorylation events

• Stimulation experiments: Compare AR detection before and after treatments that induce phosphorylation changes (such as EGF stimulation)

• Phosphatase treatments: Compare antibody binding with and without phosphatase treatment of samples

• Kinase inhibitor studies: Examine effects of specific kinase inhibitors on AR detection

• Mutagenesis approaches: Study how point mutations at or near Tyr363 affect antibody binding and AR function

This approach can provide insights into how phosphorylation events regulate AR activity in normal physiology and disease states.

What are the methodological considerations for using AR (Ab-363) Antibody in studies of drug resistance mechanisms in prostate cancer?

When investigating drug resistance mechanisms in prostate cancer using AR (Ab-363) Antibody, researchers should consider:

• Cell line selection: Include both sensitive and resistant cell lines with verified AR expression

• Treatment protocols: Standardize drug treatment conditions (concentration, duration, schedule)

• Combination with AR variant detection: Pair with AR-V7 specific antibodies to assess splice variant contributions to resistance

• Nuclear vs. cytoplasmic fractionation: Separate cellular compartments to assess AR localization changes

• Co-immunoprecipitation: Investigate altered protein-protein interactions that may contribute to resistance

• Correlation with functional assays: Link AR detection to functional outcomes such as transcriptional activity and cell proliferation

These methodological considerations enable more robust investigation of how AR signaling changes contribute to therapeutic resistance.

How can AR (Ab-363) Antibody be incorporated into multiplexed detection systems for studying androgen receptor in complex cellular contexts?

For multiplexed AR detection systems using AR (Ab-363) Antibody:

• Multiplex immunofluorescence:

  • Combine with antibodies against other signaling proteins (ERK, AKT, etc.)

  • Use spectrally distinct fluorophores for simultaneous detection

  • Apply tyramide signal amplification for weak signals

• Multi-color Western blotting:

  • Use different fluorescent secondary antibodies for simultaneous detection of multiple targets

  • Consider stripping and reprobing strategies for sequential detection

• Mass cytometry (CyTOF):

  • Label with metal-conjugated secondary antibodies for high-dimensional analysis

  • Combine with markers of cell state and other signaling pathways

• Single-cell analysis:

  • Integrate with single-cell Western blot or microfluidic antibody capture platforms

  • Correlate with single-cell transcriptomics

• Proximity ligation assays:

  • Combine with antibodies against potential interaction partners to visualize protein-protein interactions in situ

These advanced approaches allow researchers to place AR signaling within broader cellular signaling networks.

How does the specificity of AR (Ab-363) Antibody compare to recombinant monoclonal antibodies targeting androgen receptor?

When comparing AR (Ab-363) polyclonal antibody to recombinant monoclonal alternatives:

What methodological approaches should be used to compare phosphorylation-specific and total AR antibodies in the same experimental system?

To methodically compare phosphorylation-specific and total AR antibodies:

• Sequential detection protocol:

  • Start with phospho-specific antibodies (e.g., phospho-Ser94, phospho-Ser650)

  • Strip and reprobe with AR (Ab-363) for total AR detection

  • Calculate phosphorylation/total AR ratios for quantitative analysis

• Validation controls:

  • Include phosphatase-treated samples as negative controls for phospho-antibodies

  • Use stimulation conditions known to enhance specific phosphorylation sites

  • Include AR-null cell lines as negative controls for both antibody types

• Quantitative analysis:

  • Employ digital imaging systems with linear detection range

  • Use calibration standards for absolute quantification

  • Apply appropriate normalization methods for comparing across experiments

• Correlation with functional outcomes:

  • Link phosphorylation patterns to transcriptional activity

  • Associate specific phosphorylation events with cellular phenotypes

This systematic approach enables researchers to distinguish between changes in AR phosphorylation versus changes in total AR protein levels.

How should researchers integrate AR (Ab-363) antibody data with transcriptomic and proteomic datasets in systems biology approaches?

For integrating AR (Ab-363) antibody data with -omics datasets:

• Standardized sample processing:

  • Use parallel samples for antibody-based detection and -omics analysis

  • Apply consistent normalization strategies across datasets

  • Include spike-in controls for cross-platform calibration

• Correlation analysis:

  • Compare AR protein levels with AR mRNA expression

  • Correlate AR detection with expression of known AR target genes

  • Analyze relationships between AR and other proteins in signaling pathways

• Network integration:

  • Map AR interactions using both antibody-based co-immunoprecipitation and proteomic interaction data

  • Incorporate phosphorylation status into signaling network models

  • Apply Bayesian network approaches to infer causal relationships

• Visualization strategies:

  • Develop multi-level visualizations that incorporate antibody-based and -omics data

  • Apply dimension reduction techniques to identify patterns across datasets

  • Use heatmaps and network diagrams to highlight key relationships

These approaches enable researchers to place AR biology within a systems-level context, revealing emergent properties not apparent from antibody-based detection alone.

How might structure-guided antibody design principles be applied to develop next-generation AR antibodies with enhanced specificity?

Future structure-guided design of AR antibodies could leverage principles demonstrated in other antibody engineering efforts:

• Computational epitope mapping:

  • Use molecular dynamics simulations to identify stable, accessible epitopes

  • Apply in silico affinity maturation to optimize complementarity-determining regions (CDRs)

  • Design antibodies with improved shape complementarity to AR epitopes

• Directed evolution approaches:

  • Create libraries with NNK-combinatorial mutations at contact residues

  • Select for variants with enhanced affinity and specificity

  • Combine enriched mutations to generate optimized antibodies

• CDR engineering:

  • Introduce deliberate deletions in CDR-H1 regions to enhance binding properties

  • Optimize electrostatic interactions between antibody and target epitope

  • Apply electrostatic optimization to increase binding affinity

• Affinity maturation strategies:

  • Introduce mutations that eliminate unsatisfied polar groups in the binding interface

  • Optimize charged residues peripheral to the interface to increase on-rates

  • Apply structure-based rational design to guide mutagenesis

These approaches could yield AR antibodies with significantly improved specificity, affinity, and performance across multiple applications.

What methodological considerations should guide the development of AR (Ab-363) antibody-based assays for clinical biomarker applications?

For translating AR (Ab-363) antibody into clinical biomarker applications:

• Assay standardization requirements:

  • Establish reference standards for quantitative calibration

  • Determine minimal sample requirements and preservation methods

  • Develop automated protocols to reduce operator variability

• Clinical validation approach:

  • Define clear clinical questions (diagnosis, prognosis, treatment selection)

  • Design studies with appropriate statistical power and patient stratification

  • Include relevant clinical outcomes and time-to-event analyses

• Quality control measures:

  • Implement internal and external quality control samples

  • Establish acceptance criteria for analytical performance

  • Define procedures for lot testing and antibody qualification

• Comparative effectiveness studies:

  • Compare performance against existing biomarkers

  • Assess added value in multivariate prediction models

  • Evaluate cost-effectiveness for clinical implementation

• Regulatory considerations:

  • Document analytical validation according to applicable guidelines

  • Address reproducibility across multiple clinical laboratories

  • Prepare verification protocols for laboratory-developed tests

These methodological considerations are essential for translating research findings into clinically applicable biomarker assays.

How can researchers effectively combine AR (Ab-363) antibody with emerging single-cell technologies to advance understanding of AR heterogeneity in tissues?

To leverage AR (Ab-363) antibody in single-cell analysis:

• Integration with single-cell sequencing:

  • Apply CITE-seq or REAP-seq for simultaneous protein and RNA detection

  • Use index sorting to correlate antibody staining with single-cell transcriptomics

  • Develop computational methods to integrate protein and RNA measurements

• Spatial analysis approaches:

  • Combine with multiplexed immunofluorescence for spatial context

  • Apply imaging mass cytometry for high-parameter spatial analysis

  • Implement cyclic immunofluorescence for extended antibody panels

• Functional correlation methods:

  • Link AR detection to single-cell functional assays

  • Correlate with chromatin accessibility at single-cell level

  • Combine with live-cell imaging for temporal dynamics

• Heterogeneity quantification:

  • Develop metrics for quantifying AR expression heterogeneity

  • Apply information theory approaches to measure signaling diversity

  • Create visualization tools for multi-parameter single-cell data

• Validation requirements:

  • Establish sensitivity limits for single-cell detection

  • Compare results across complementary single-cell platforms

  • Validate findings using orthogonal approaches

These approaches can reveal previously unappreciated heterogeneity in AR expression and signaling that may have important implications for disease mechanisms and therapeutic responses.